Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AMRX Hot Sheet
Price: $19.20 -5%
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Amneal Pharmaceuticals (NASDAQ: AMRX) to $11.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Amneal Pharmaceuticals (AMRX) PT Raised to $25 at JPMorgan
- Revvity Inc (RVTY) PT Raised to $177 at Stifel
- Amneal Reports Third Quarter 2026 Financial Results
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
